Literature DB >> 16157218

Synthetic bile acid derivatives induce apoptosis through a c-Jun N-terminal kinase and NF-kappaB-dependent process in human cervical carcinoma cells.

Eunok Im1, Sang-Ho Choi, Hongsuk Suh, Yung Hyun Choi, Young Hyun Yoo, Nam Deuk Kim.   

Abstract

Recently, we have reported that a synthetic derivative of ursodeoxycholic acid (UDCA), HS-1183, and those of chenodeoxycholic acid (CDCA), HS-1199 and HS-1200, induced apoptosis in human breast carcinoma cells through a p53-independent pathway. Here, we present that the synthetic bile acid derivatives induce apoptosis in SiHa human cervical carcinoma cells as well. The parental compounds, UDCA and CDCA, exhibited no significant effect on the cell viability at the concentration ranges tested. However, their synthetic bile acid derivatives significantly decreased cell viability in a concentration dependent manner. Characteristic manifestations of apoptosis including DNA fragmentation, an increased level of proapoptotic protein Bax, and cleavage of poly(ADP-ribose) polymerase were shown when the cells were treated with these synthetic compounds. Nuclear translocation of nuclear transcription factor NF-kappaB was increased and this suggests that the synthetic compounds induce apoptosis in a NF-kappaB dependent pathway. Phosphorylations of p38 and extracellular signal-regulated kinase were not affected, whereas c-Jun N-terminal kinase (JNK) was activated along with an increased level of transcription factor c-Jun. Our studies demonstrate that the newly synthesized bile acids are capable of inhibiting cell proliferation and inducing apoptosis in SiHa cells through activation of JNK and NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157218     DOI: 10.1016/j.canlet.2004.11.055

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Synthesis and evaluation of bile acid amides of [Formula: see text]-cyanostilbenes as anticancer agents.

Authors:  Devesh S Agarwal; Rajnish Prakash Singh; K Lohitesh; Prabhat N Jha; Rajdeep Chowdhury; Rajeev Sakhuja
Journal:  Mol Divers       Date:  2017-12-13       Impact factor: 2.943

2.  Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice.

Authors:  Hui Liu; Hong-Wei Xu; Yu-Zhen Zhang; Ya Huang; Guo-Qing Han; Tie-Jun Liang; Li-Li Wei; Cheng-Yong Qin; Cheng-Kun Qin
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 3.  Mechanism of Bile Acid-Induced Programmed Cell Death and Drug Discovery against Cancer: A Review.

Authors:  Jung Yoon Jang; Eunok Im; Yung Hyun Choi; Nam Deuk Kim
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

Review 4.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

5.  Comparison of Cytotoxic Activity of Bile on HepG2 and CCRF-CEM Cell Lines: An in Vitro Study.

Authors:  Negar Azarpira; Fatemeh Rastegar; Maryam Amiri; Elaheh Esfandiari; Bita Geramizadeh
Journal:  Iran J Med Sci       Date:  2012-12

6.  U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways.

Authors:  Yang Xu; Qiang Luo; Ting Lin; Zhiping Zeng; Guanghui Wang; Dequan Zeng; Rong Ding; Cuiling Sun; Xiao-Kun Zhang; Haifeng Chen
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

7.  Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis.

Authors:  Huan Zhang; Huanji Xu; Chenliang Zhang; Qiulin Tang; Feng Bi
Journal:  Cell Death Discov       Date:  2021-08-07

8.  Synthesis and Anti-Hepatoma Activities of U12 Derivatives Arresting G0/G1 Phase and Inducing Apoptosis by PI3K/AKT/mTOR Pathway.

Authors:  Renjing Yang; Chunchun Du; Ting Cao; Guanghui Wang; Xin Jiang; Jun Gao; Ting Lin; Cuiling Sun; Rong Ding; Wenjing Tian; Haifeng Chen
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.